Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Amid heated debates on whether people should get booster shots of vaccine, in the face of a fresh outbreak of Omicron variant of the Covid-19 virus, a new Lancet study weighs in favour of additional jabs.
The study was conducted on the people who got Covishield, developed by Astrazeneca and manufactured by Serum Institute of India.
The latest study, which was conducted in Brazil and Scotland, reportedly showed that the effectiveness of the vaccine reduced 18-19 weeks after the second shot of Astrazeneca vaccine.
Reduced effectiveness can be read as higher chances of need for hospitalisation and even deaths. The study went on to conclude that those who took the Covishield vaccine may need to consider booster shots.
The study gains significance especially in the context of India as almost 89% of the administered vaccine doses in the country is Covishield.

Efficacy of Covishield for Omicron reduces 3-5 months after 2nd jab: Lancet study

In the face of a fresh outbreak of Omicron variant of the Covid-19 virus, a new Lancet study weighs in favour of additional jabs

Lancet: Covishield&nbsp;2nd jab ineffective after 3-5 months for Omicron
The study conducted on people who received Covishield&nbsp;jab
The study sets an alarm as most have received Covishield&nbsp;jab in India

Omicron: The latest study reportedly showed that the effectiveness of the vaccine reduced 18-19 weeks after the second shot of Astrazeneca vaccine

Amid heated debates on whether people should get booster shots of vaccine, in the face of a fresh outbreak of Omicron variant of the Covid-19 virus, a new Lancet study weighs in favour of additional jabs.
The study was conducted on the people who got Covishield, developed by Astrazeneca and manufactured by Serum Institute of India.
The latest study, which was conducted in Brazil and Scotland, reportedly showed that the effectiveness of the vaccine reduced 18-19 weeks after the second shot of Astrazeneca vaccine.
Also watch:&nbsp;<a href="https://www.editorji.com/india-news/200-omicron-cases-in-india-so-far-over-5-000-new-covid-19-infections-1640074528753" target="_blank">200 Omicron cases in India so far, over 5,000 new Covid-19 infections</a>
Reduced effectiveness can be read as higher chances of need for hospitalisation and even deaths. The study went on to conclude that those who took the Covishield vaccine may need to consider booster shots.
The study gains significance especially in the context of India as almost 89% of the administered vaccine doses in the country is Covishield.

The Subject Expert Committee of India's drug control panel has denied permission to Serum Institute of India for administer a booster dose of its Covid-10 vaccine, Covishield. 
According to a report by India Today, the SEC has questioned administration of a third dose when several nations are facing a threat by Omicron variant of the novel coronavirus. 
The committee has asked SII to submit data pertaining to local clinical trials for booster doses. 
The India Today report state that the committee observed that SII has only presented immunogenicity data of 75 subjects from the UK study and no data has been submitted on need for booster doses in Indian population. 
 

Serum Institute denied permission for booster dose, asked to conduct trial first: Report

India's drug control panel has denied permission to Serum Institute of India for administer a booster dose of its Covid-10 vaccine, Covishield. 

Drug control committee denies permission to Serum Institute for booster doses Serum Institute asked to conduct trial in India on booster doses: Report Expert committee: no data pertaining to Indian population submitted

According to a report by India Today, the SEC has questioned administration of a third dose when several nations are facing a threat by&nbsp;Omicron variant of the novel coronavirus.&nbsp;

The Subject Expert Committee of India's drug control panel has denied permission to Serum Institute of India for administer a booster dose of its Covid-10 vaccine, Covishield.&nbsp;
According to a report by India Today, the SEC has questioned administration of a third dose when several nations are facing a threat by&nbsp;Omicron variant of the novel coronavirus.&nbsp;
Also watch:&nbsp;<a href="https://www.editorji.com/coronavirus/omicron-reduces-vaccine-efficacy-spreads-faster-who-1639331525561">Omicron reduces vaccine efficacy, spreads faster: WHO</a>
The committee has asked SII to submit data pertaining to local clinical trials for booster doses.&nbsp;
The India Today report state that the committee observed that SII&nbsp;has only&nbsp;presented immunogenicity data of 75 subjects from the UK study and no data has been submitted on need for booster doses in Indian population.&nbsp;
&nbsp;

President of the 76th session of the UN General Assembly Abdulla Shahid has said he received the two doses of the Covishield vaccine manufactured in India
He also added that a &ldquo;large portion&rdquo; of other countries around the world have also received India&rsquo;s Covid-19 vaccine, Covishield.
The Covishield vaccine, developed by AstraZeneca, is manufactured in India by Pune-based Serum Institute of India.
Shahid was responding to a question on whether any Covid-19 vaccine should be recognised and considered or only the ones validated by the World Health Organization or any other group.
Shahid said he took Covishield and &lsquo;survived&rsquo; but added that a &lsquo;someone else, a medical person make that call&rsquo; on recognizing vaccine
India has exported over 66 million vaccine doses to nearly 100 countries through grants, commercial shipments and the COVAX facility.

'I got India's Covishield vaccine': UNGA President Abdulla Shahid

President of the 76th session of the UN General Assembly Abdulla Shahid has said he had received the two doses of the Covishield vaccine manufactured in India

//UNGA president Abdulla Shahid: received 2 doses of Covishield&nbsp;&amp; survived
//Shahid: a &ldquo;large portion&rdquo; of other countries also received Covishield
//Covishield,&nbsp;developed by AstraZeneca, is manufactured by Pune-based SII
//Shahid: a medical person should make that call on recognizing vaccine
//India has exported over 66 million Covid vaccine doses to nearly 100 countries
&nbsp;

India has exported over 66 million vaccine doses to nearly 100 countries through grants, commercial shipments and the COVAX facility.

President of the 76th session of the UN General Assembly Abdulla Shahid has said he received the two doses of the Covishield vaccine manufactured in India
He also added that a &ldquo;large portion&rdquo; of other countries around the world have also received India&rsquo;s Covid-19 vaccine, Covishield.
The Covishield vaccine, developed by AstraZeneca, is manufactured in India by Pune-based Serum Institute of India.
Also Read&nbsp;<a href="https://www.editorji.com/india-news/italy-recognises-india-s-covishield-jabbed-travelers-eligible-for-green-pass-1632489132790" target="_blank">Italy recognises India's Covishield, jabbed travelers eligible for green pass</a>
Shahid was responding to a question on whether any Covid-19 vaccine should be recognised and considered or only the ones validated by the World Health Organization or any other group.
Shahid said he took Covishield and &lsquo;survived&rsquo; but added that&nbsp; &lsquo;someone else, a medical person' should make that call&rsquo; on recognizing vaccine
India has exported over 66 million vaccine doses to nearly 100 countries through grants, commercial shipments and the COVAX facility.

Italy on Friday recognised the Covishield Covid-19 vaccine. The number of European Union accepting the Covishield as valid proof of immunity of incoming travellers has moved to 19.
Indian vaccine cardholders are now eligible for the green pass, the Indian Embassy in Rome tweeted to inform.&nbsp; The tweet read that &lsquo;as an outcome of G20 health ministers&rsquo; meeting coupled with Indian foreign ministry persistent efforts, Italy has recognised India's Covishield&rsquo;
A green pass proves the holder has been fully vaccinated or recovered from Covid, granting them access to indoor restaurants, bars, cafes and other indoor venues.
Covishield, which is the AstraZeneca vaccine produced in India, is the most widely recognised vaccine for travel in the EU after those approved by European Medicines Agency (EMA).
Meanwhile, the United Kingdom is facing severe backlash over its latest international travel advisory. Even though the UK kept Covishield, manufactured by the SII, in its list of &lsquo;approved vaccines&rsquo;, it kept India in the list of countries whose travellers need to quarantine for 10 days when they reach the UK.

Italy recognises India's Covishield, jabbed travelers eligible for green pass

Italy recognised the Covishield Covid-19 vaccine. The number of European Union accepting the Covishield as valid proof of immunity of incoming travellers has moved to 19.

Italy recognised India's&nbsp;Covishield Covid-19 vaccine
19 EU nations have accepted Covishield&nbsp;as valid proof of immunity
Indian vaccine cardholders are 'now eligible for the green pass'
Covishield, EU's most widely recognised vaccine after those approved by EMA
UK facing backlash over its latest international travel advisory
UK:&nbsp;travellers from India need to quarantine for 10 days upon arrival
&nbsp;
&nbsp;

Covishield, which is the AstraZeneca vaccine produced in India, is the most widely recognised vaccine for travel in the EU after those approved by EMA.

Italy on Friday recognised the Covishield Covid-19 vaccine. The number of European Union countries accepting the Covishield as valid proof of immunity of incoming travellers has moved to 19.
Indian vaccine cardholders are now eligible for the green pass, the Indian Embassy in Rome tweeted to inform.&nbsp; The tweet read that &lsquo;as an outcome of G20 health ministers&rsquo; meeting coupled with Indian foreign ministry's persistent efforts, Italy has recognised India's Covishield&rsquo;
A green pass proves the holder has been fully vaccinated or recovered from Covid, granting them access to indoor restaurants, bars, cafes and other indoor venues.
Covishield, which is the AstraZeneca vaccine produced in India, is the most widely recognised vaccine for travel in the EU after those approved by European Medicines Agency (EMA).
Meanwhile, the United Kingdom is facing severe backlash over its latest international travel advisory. Even though the UK kept Covishield, manufactured by the SII, in its list of &lsquo;approved vaccines&rsquo;, it kept India in the list of countries whose travellers need to quarantine for 10 days when they reach the UK.

After much controversy, UK Govt has accepted India manufactured&nbsp;Covishield&nbsp;as an approved vaccine.
The updated guidelines by the&nbsp;UK state, "Formulations of the four listed vaccines, such as AstraZeneca Covishield, AstraZeneca Vaxzevria and Modern Takeda, qualify as approved vaccines."
The expanded list of accepted vaccines come into force from October 4. The travellers however must have finished the 2 dose course at least 14 days prior to travel.&nbsp;
Reports however indicate the reason behind Serum produced Covishield&nbsp;being left out of the 'accepted' list was due to the UK government raising doubts on the CoWin certification process and not due to any production quality concerns.&nbsp;&nbsp;
Adar Poonawalla, CEO of the world's largest vaccine producer Serum appealed to global leaders to harmonise vaccine certification on priority.
Poonawalla&nbsp;was quoted as saying&nbsp;&ldquo;It is not regulatory filing or quality systems but vaccine certificate systems that western nations are struggling to find a way out."

UK to allow travellers vaccinated with Covishield from Oct 4

After much controversy, UK Govt has accepted India manufactured&nbsp;Covishield&nbsp;as an approved vaccine.

"Formulations of the four listed vaccines, such as AstraZeneca Covishield, AstraZeneca Vaxzevria and Modern Takeda, qualify as approved vaccines."

After much controversy, UK Govt has accepted India manufactured&nbsp;Covishield&nbsp;as an approved vaccine.
The updated guidelines by the&nbsp;UK state, "Formulations of the four listed vaccines, such as AstraZeneca Covishield, AstraZeneca Vaxzevria and Modern Takeda, qualify as approved vaccines."
The expanded list of accepted vaccines come into force from October 4. The travellers however must have finished the 2 dose course at least 14 days prior to travel.&nbsp;
Reports however indicate the reason behind Serum produced Covishield&nbsp;being left out of the 'accepted' list was due to the UK government raising doubts on the CoWin certification process and not due to any production quality concerns.&nbsp;&nbsp;
Adar Poonawalla, CEO of the world's largest vaccine producer Serum appealed to global leaders to harmonise vaccine certification on priority.
Poonawalla&nbsp;was quoted as saying&nbsp;&ldquo;It is not regulatory filing or quality systems but vaccine certificate systems that western nations are struggling to find a way out."

Vaccination passport: EU said its medical body has not received a request for the approval of Serum Insitute's Covishield for the ]Green Pass'

Travel concerns of vaccinated Indians: EU says not received Covishield approval request

Vaccination passport: EU said its medical body&nbsp;has not received a request for the approval of Serum Insitute's&nbsp;Covishield&nbsp;for the ]Green Pass'

EU Medical Body says not received Covishield approval request

Concerns after&nbsp;EU's 'Green Pass' Plan leaves out SII's&nbsp;Covishield
Covishield-vaccinated Indians facing issues with travel to Europe
SII&nbsp;chief Adar Poonawalla tweeted he had taken this up at the highest levels
EU: medical body hasn't received&nbsp;request for the approval of Covishield
EU: will examine any such request when received, as per its procedures
&nbsp;
&nbsp;

Vaccination passport: EU said its medical body&nbsp;has not received a request for the approval of Serum Insitute's&nbsp;Covishield&nbsp;for the ]Green Pass'

Amid concerns among Covishield-vaccinated Indians facing issues with travel to Europe, the EU said on Tuesday the medical body of the union, EMA has not received a request for the approval of Covishield&nbsp; in the COVID-19 'vaccination passport'. It will examine any such request when received, as per its procedures," the EU said in a statement.
The European Union has not yet recognised the India-made version of the AstraZeneca-Oxford University vaccine.
Serum Institute chief Adar Poonawalla tweeted that he had "taken this up at the highest levels, with regulators and at diplomatic levels" and that he hoped the matter would be resolved soon.
So far, only those vaccinated by either Pfizer, Moderna, AstraZeneca-Oxford and Johnson &amp; Johnson vaccines will be allowed restriction-free travel within the EU during the pandemic.
&nbsp;

India now has the third Covid-19 vaccine in its armor, with the DCGI giving a go ahead to Sputnik V for emergency use in the country. 

Know your vaccines: How do Sputnik V, Covaxin and Covishield work?

India now has the third Covid-19 vaccine in its armor, with the DCGI giving a go ahead to Sputnik V for emergency use in the country.&nbsp;Sputnik V joins Bharat Biotech&rsquo;s Covaxin and Oxford-AstraZeneca&rsquo;s Covishield &mdash; at a time when there is a worrying spike in cases across India.
 We'll break down for you what each vaccine is and how they work.

India now has the third <a href="https://www.editorji.com/covid-19" target="_blank">Covid-19 vaccine</a> in its armor, with the DCGI giving a go ahead to Sputnik V for emergency use in the country.&nbsp;
<a href="https://www.editorji.com/story/sputnik-v-what-you-need-to-know-about-the-russian-vaccine-1618243022603" target="_blank">Sputnik V</a> joins Bharat Biotech&rsquo;s Covaxin and Oxford-AstraZeneca&rsquo;s Covishield &mdash; at a time when there is a worrying spike in cases across India.
We'll break down for you what each vaccine is and how they work.
Also Read | <a href="https://www.editorji.com/story/850-million-doses-of-sputnik-v-covid-vaccine-annually-limited-shots-by-month-end-1618298567193" target="_blank">850 million doses of Sputnik V Covid vaccine annually, limited shots by month-end</a>

The government's top committee on Covid-19 vaccines has increased the interval between administering two doses of Covishield to four to eight weeks.

Covishield New Guidelines | Centre revises 2nd dose interval for Covishield to 4-8 weeks

The government's top committee on Covid-19 vaccines has increased the interval between administering two doses of Covishield to four to eight weeks, from the existing four to six weeks, to increase the efficacy of the vaccine.
Union ministry of health and family welfare in a statement on Monday that changes in the dosage period&nbsp;of vaccine manufactured by the Serum Institute of India has been initiated due to&nbsp;the emerging scientific evidence.&nbsp;
However, the health ministry also emphasised that this decision of revised time interval between two doses was applicable only to Covishield, and not Covaxin, that is co-developed by Bharat Biotech and the Indian Council of Medical Research.

Centre revises 2nd dose interval for Covishield to 4-8 weeks

Govt recommends&nbsp;revision in 2nd dose interval for Covishield
Centre revises&nbsp;the gap to increase the efficacy of the vaccine
Govt revises 2nd dose interval for Covishield to 4-8 weeks
Earlier the interval between two doses&nbsp;were up to 12 weeks

The government's top committee on <a href="https://www.editorji.com/covid-19" target="_blank" >Covid-19 vaccines</a> has increased the interval between administering two doses of Covishield to four to eight weeks, from the existing four to six weeks, to increase the efficacy of the vaccine.
Union ministry of health and family welfare in a statement on Monday that changes in the dosage period&nbsp;of vaccine manufactured by the Serum Institute of India has been initiated due to&nbsp;the emerging scientific evidence.&nbsp;
However, the health ministry also emphasised that this decision of revised time interval between two doses was applicable only to Covishield, and not Covaxin, that is co-developed by Bharat Biotech and the Indian Council of Medical Research.
Also Read: <a href="https://www.editorji.com/story/no-2nd-covid-19-wave-in-delhi-yet-says-health-min-satyendar-jain-1616421377009" target="_blank" >'No 2nd covid-19 wave in Delhi yet', says Health Min Satyendar Jain</a>

Nationalism and export restrictions can hit of 2 million vaccine target set by the WHO, that is the word coming in from Adar Poonawalla.

Serum CEO raises red flags on reaching Covid-19 vaccination goals for 2021

As the world's largest vaccination program continues to be underway, Serum CEO warns that timelines and commitments can be derailed due to lack of global co-operation.&nbsp;

Nationalism and export restrictions can hit of 2 million vaccine target set by the WHO, that is the word coming in from Adar Poonawalla. The Serum CEO&nbsp;cited lack of supplies and&nbsp;restricted access to materials required for vaccine productions as the biggest hurdle at this point.
Poonawalla,&nbsp;in an interview to Bloomberg said, "Many manufacturers, including Serum, already have missed timelines and commitments due to material shortfalls."
&nbsp;

Nationalism and export restrictions can hit the 2 million vaccine target set by the WHO, that is the word coming in from Adar Poonawalla.
The Serum CEO&nbsp;cited lack of supplies and&nbsp;restricted access to materials required for vaccine productions as the biggest hurdle at this point.
Poonawalla,&nbsp;in an interview to Bloomberg said, "Many manufacturers, including Serum, already have missed timelines and commitments due to material shortfalls."
Also Read: <a href="https://www.editorji.com/story/sii-ceo-adar-poonawalla-takes-covishield-to-endorse-its-safety-1610791044119" target="_blank" >SII CEO Adar Poonawalla takes Covishield to 'endorse its safety'</a>

Billboards with PM Modi's picture have come up in Greater Toronto area to thank India for providing Covid-19 vaccines to Canada.

Canadians thank PM Narendra Modi for Covid vaccine support with billboards in Greater Toronto

Billboards&nbsp;with PM Modi's&nbsp;picture have come up in Greater Toronto area to thank India for providing Covid-19 vaccines to Canada.

Canadians thank Modi for vaccine support with billboards in GTA

Billboards&nbsp;with PM Modi's&nbsp;picture have come up in Greater Toronto area to thank India for providing Covid-19 vaccines to Canada.
India has been receiving&nbsp;a lot of praise and accolades from the international community for being pro-active in manufacturing and then supplying vaccines.&nbsp;
Last week, Canada received 5 lakh doses of Covishield vaccine from India. Covishield&nbsp;is one of two indigenously&nbsp;manufactured vaccines of India.&nbsp;
Recently Prime Minister Narendra Modi&nbsp;said that 'Made-in-India' vaccines have been supplied to over 50 countries so far.
&nbsp;

Billboards&nbsp;with <a href="https://www.editorji.com/topic/narendra-modi-1527239294024" target="_blank" >PM Modi's</a>&nbsp;picture have come up in Greater Toronto area to thank India for providing <a href="https://www.editorji.com/covid-19" target="_blank" >Covid-19 vaccines</a> to Canada.
India has been receiving&nbsp;a lot of praise and accolades from the international community for being pro-active in manufacturing and then supplying vaccines.&nbsp;
Last week, Canada received <a href="https://www.editorji.com/story/serum-institute-to-ship-covid-jabs-to-canada-in-less-than-a-month-1613388875657" target="_blank" >5 lakh doses of Covishield vaccine from India</a>. Covishield&nbsp;is one of two indigenously&nbsp;manufactured vaccines of India.&nbsp;
Recently Prime Minister <a href="https://www.editorji.com/story/justin-trudeau-calls-pm-narendra-modi-india-assures-canada-of-covid-vaccine-supply-1613016905695" target="_blank" >Narendra Modi</a>&nbsp;said that 'Made-in-India' vaccines have been supplied to over 50 countries so far.

Corona Vaccine Update: The first batches of Bharat BioTech's Covaxin left Hyderabad early on Wednesday morning for Delhi and 10 other cities. 

Corona Vaccine Update: Day after Serum, Bharat Biotech rolls out Indian Covid vaccine

A day after Serum Institute rolled out Covid vaccine, the first batches of Bharat BioTech's Covaxin left Hyderabad early on Wednesday morning for Delhi and 10 other cities.

Day after Serum, Bharat Biotech rolls out Indian Covid vaccine 

A day after Serum Institute rolled out Covid vaccine, the first batches of Bharat BioTech's Covaxin left Hyderabad early on Wednesday morning for Delhi and 10 other cities. The consignment was flown to Delhi by Air India. Reports said that a consignment of three boxes, weighing 80.5 kg was flown to Delhi. Apart from Delhi, the vaccines are being sent to Bengaluru, Chennai, Patna, Jaipur and Lucknow, officials said. The govt has procured 1.1 crore doses of Serum's Covishield and 5.5 lakh doses of Covaxin ahead of the inoculation drive that will begin on January 16.

A day after Serum Institute rolled out <a href="https://www.editorji.com/covid-19" target="_blank" >Covid vaccine</a>, the first batches of Bharat BioTech's Covaxin left Hyderabad early on Wednesday morning for Delhi and 10 other cities.
The consignment was flown to Delhi by Air India. Reports said that a consignment of three boxes, weighing 80.5 kg was flown to Delhi. Apart from Delhi, the vaccines are being sent to Bengaluru, Chennai, Patna, Jaipur and Lucknow, officials said.
The govt has procured 1.1 crore doses of Serum's <a href="https://www.editorji.com/story/first-covid-shots-reach-14-cities-stage-set-for-jan-16-drive-1610505678804" target="_blank" >Covishield</a> and 5.5 lakh doses of Covaxin ahead of the inoculation drive that will begin on January 16.

Adar Poonawalla on Tuesday said his firm has decided to sell the first 100 million doses of Covishield vaccine at a special price to the Indian government. 

Giving vaccine at ₹200/dose for first 100 mn doses only to India: Adar Poonawalla

CEO of the Serum Institute of India (SII), Adar Poonawalla on Tuesday said his firm has decided to sell the first 100 million doses of Covishield vaccine at a special price to the Indian government. Poonawalla said SII will be selling these 100 million doses at ₹200 per dose, following the government's request. However, following this, the Serum Institute of India will sell the vaccine at ₹1,000 per dose to private players. Early Tuesday morning, the first consignment of Covishield, the Covid-19 vaccine developed by Oxford University and AstraZenca and manufactured in India by the Serum Institute, was dispatched to 13 locations from the Pune-based firm.

Giving vaccine at ₹200/dose for first 100 mn doses only to India: SII

SII: Giving first 100 mn doses of&nbsp;Covishield&nbsp;at special price
SII: doses at ₹200 per dose, following the govt's request
SII&nbsp;will sell the vaccine at ₹1,000/dose to private players
First consignment of Covishield&nbsp;dispatched to 13 locations
&nbsp;

CEO of the Serum Institute of India (SII), Adar Poonawalla on Tuesday said his firm has decided to sell the first 100 million doses of Covishield vaccine at a special price to the Indian government.
Poonawalla said SII will be selling these 100 million doses at ₹200 per dose, following the government's request. However, following this, the Serum Institute of India will sell the vaccine at ₹1,000 per dose to private players.
Early Tuesday morning, the first consignment of Covishield, the Covid-19 vaccine developed by Oxford University and AstraZenca and manufactured in India by the Serum Institute, was dispatched to 13 locations from the Pune-based firm.

covishield vaccine

Categories